Literature DB >> 1338275

Topoisomerase II alpha and beta in human tumor cells grown in vitro and in vivo.

E Prosperi1, E Sala, C Negri, C Oliani, R Supino, G B Astraldi Ricotti, G Bottiroli.   

Abstract

The cellular content and the cell-cycle distribution of the 170 kD- and 180 kD-isoforms of DNA topoisomerase II were investigated in human tumor cells with specific monoclonal antibodies and by immunofluorescent detection with flow cytometry. Levels of topo II alpha were almost three-fold higher than the beta-isozyme in exponentially growing cells in vitro. In contrast, topo II alpha but not beta, was markedly reduced in plateau-phase cells. Tumor cells from surgical biopsies, mainly in G0/G1 phase, exhibited a 95% beta- versus 5% alpha-isoform expression. These results support the hypothesis that topo II alpha is mainly related to DNA synthesis, and topo II beta to DNA transcription.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1338275

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

3.  Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

Authors:  Carmen K M Mak; Victor K L Hung; Joseph T Y Wong
Journal:  Chromosoma       Date:  2005-11-15       Impact factor: 4.316

4.  Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

Authors:  C D Evans; S E Mirski; M K Danks; S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Authors:  S Léonce; V Perez; M R Casabianca-Pignede; M Anstett; E Bisagni; A Pierré; G Atassi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Ronald P Mason
Journal:  Biochem Biophys Rep       Date:  2017-04-20

7.  Immunohistochemical study of DNA topoisomerase II in human gastric disorders.

Authors:  N Yabuki; H Sasano; K Kato; S Ohara; T Toyota; H Nagura; M Miyaike; N Nozaki; A Kikuchi
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

8.  Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

Authors:  Ashutosh Kumar; Marilyn Ehrenshaft; Erik J Tokar; Ronald P Mason; Birandra K Sinha
Journal:  Biochim Biophys Acta       Date:  2016-04-17

9.  Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.

Authors:  E W Eijdems; M de Haas; A J Timmerman; G P Van der Schans; E Kamst; J de Nooij; G C Astaldi Ricotti; P Borst; F Baas
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.